Bio-Techne Corporation, a global provider of life science tools, reagents, and diagnostic products, today announced the launch of new additions to its R&D Systems™ AI Engineered Designer Protein portfolio designed to improve reproducibility and performance across advanced cell culture and cell therapy development workflows.
The R&D Systems AI-Engineered Designer Protein platform enables the design and creation of new protein-based solutions, helping researchers overcome current variability and scalability challenges in advanced cell culture by improving the stability and activity of critical reagents.
By improving protein performance properties such as thermal stability, activity, and solubility, Bio-Techne helps researchers achieve consistent results and scalable workflows from discovery to therapeutic development. These improvements will be important as cell therapies and organoid systems move to clinical and commercial scales, where small changes in cell signaling inputs can have large effects on outcomes.
These additions follow previous expansions of the R&D Systems AI-Engineered Design Protein portfolio and build on Bio-Techne’s strategy to develop a comprehensive portfolio of next-generation signaling technologies. These innovations, such as hyperactive cytokines, thermostable growth factors, and signaling pathway agonists, support stem cell culture, organoid development, and regenerative medicine workflows by enabling more controlled and reproducible systems across the continuum from basic research to process development to large-scale manufacturing.
Early adopters of R&D Systems AI Engineered Designer Proteins are already seeing visible improvements in cell expansion and overall workflow performance across demanding applications.
“Many patient-derived tumor-infiltrating lymphocyte (TIL) samples fail during initial expansion due to insufficient cell proliferation.” “We’re thrilled to be working with the University of Minnesota,” said Dr. Branden Moriarity, associate professor in the Division of Pediatric Hematology-Oncology at the University of Minnesota. “IL-2 thermostable agonist proteins offer promising proliferative advantages for TIL samples and also provide clear operational advantages that reduce product costs for TIL treatments.”
This real-world feedback highlights the broad potential of the R&D Systems AI-Engineered Designer Protein platform. With recent enhancements including additional cytokines and growth factors, this platform is designed to enable advanced cell culture workflows that are more consistent, scalable, and cost-effective.
As cell therapies progress from early research to clinical and commercial production, it is critical to achieve consistency, robustness, and scalability across increasingly complex workflows. Our AI-engineered designer proteins are designed to overcome these challenges by providing enhanced stability, activity, and performance, enabling more reproducible results and supporting seamless scale-up from discovery to production. ”
Will Geist, President of Biotechne’s Protein Science Division
Newly launched proteins include:
- FGF-4 Thermostable – Designed to support pluripotent stem cell maintenance, embryonic development studies, and differentiation workflows requiring sustained growth factor activity.
- FGF-7 Thermostable – Designed to support epithelial and tissue regeneration workflows such as advanced 3D culture systems and organoid expansion that require sustained stability at elevated temperatures.
- FGF-8b Thermostable – Optimized for developmental biology, organoid modeling, and regenerative medicine applications where precise morphogenetic signaling is critical.
- IL-3 Thermostable – Designed to support hematopoietic stem and progenitor cell proliferation and differentiation across early stage and lineage-committed cell populations that require sustained cytokine stability in culture.
- IL-15 Hyperactive – Designed to promote NK and T cell proliferation, enhanced signaling strength and persistence supports critical cell therapy workflows and immunotherapy research.
The expansion of the AI-engineered designer protein portfolio strengthens Biotechne’s leadership in developing high-performance signaling molecules for advanced biological systems. These innovations support organoid culture, stem cell differentiation, and cell therapy manufacturing. This is an area where reproducible scale-up from discovery to production is increasingly required as a requirement for success.
